⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory high risk myelodysplastic syndrome

Every month we try and update this database with for refractory high risk myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSNCT02921061
Mixed Phenotype...
Previously Trea...
Recurrent Adult...
Recurrent High ...
Refractory Acut...
Refractory High...
Untreated Adult...
Cladribine
Cytarabine
Decitabine
Filgrastim
Laboratory Biom...
Mitoxantrone Hy...
18 Years - Fred Hutchinson Cancer Center
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT04047641
Acute Myeloid L...
Blasts 20 Perce...
High Risk Myelo...
Recurrent Acute...
Recurrent Acute...
Recurrent High ...
Refractory Acut...
Refractory High...
Cladribine
Cytarabine
Idarubicin
Quizartinib
18 Years - M.D. Anderson Cancer Center
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeNCT03383575
Acute Myeloid L...
Blasts 20-30 Pe...
Chronic Myelomo...
IDH2 Gene Mutat...
Myelodysplastic...
Recurrent High ...
Refractory High...
Azacitidine
Enasidenib
Quality-of-Life...
12 Years - M.D. Anderson Cancer Center
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaNCT03896269
Blasts 10-19 Pe...
Blasts More Tha...
High Risk Chron...
Recurrent Chron...
Recurrent High ...
Refractory Chro...
Refractory High...
Liposome-encaps...
18 Years - M.D. Anderson Cancer Center
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSNCT02921061
Mixed Phenotype...
Previously Trea...
Recurrent Adult...
Recurrent High ...
Refractory Acut...
Refractory High...
Untreated Adult...
Cladribine
Cytarabine
Decitabine
Filgrastim
Laboratory Biom...
Mitoxantrone Hy...
18 Years - Fred Hutchinson Cancer Center
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeNCT03359460
Myelodysplastic...
Previously Trea...
Refractory High...
Secondary Myelo...
Therapy-Related...
Ibrutinib
Lenalidomide
18 Years - University of California, Davis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: